154 related articles for article (PubMed ID: 33268933)
1. Expression of Cyclin D1 in Hyperplasia and Carcinoma of Endometrium and Its Correlation with Histologic Grade, Tumor Type, and Clinicopathological Features.
Sangwan K; Garg M; Pathak N; Bharti L
J Lab Physicians; 2020 Dec; 12(3):165-170. PubMed ID: 33268933
[No Abstract] [Full Text] [Related]
2. Expression of cyclin D1 in normal, metaplastic, hyperplastic endometrium and endometrioid carcinoma suggests a role in endometrial carcinogenesis.
Ruhul Quddus M; Latkovich P; Castellani WJ; James Sung C; Steinhoff MM; Briggs RC; Miranda RN
Arch Pathol Lab Med; 2002 Apr; 126(4):459-63. PubMed ID: 11900573
[TBL] [Abstract][Full Text] [Related]
3. Cyclin D1 and Ki-67 expression in normal, hyperplastic and neoplastic endometrium.
Shevra CR; Ghosh A; Kumar M
J Postgrad Med; 2015; 61(1):15-20. PubMed ID: 25511212
[TBL] [Abstract][Full Text] [Related]
4. Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables.
Ozuysal S; Oztürk H; Bilgin T; Filiz G
Arch Gynecol Obstet; 2005 Feb; 271(2):123-6. PubMed ID: 14740230
[TBL] [Abstract][Full Text] [Related]
5. Expression of cyclin D1 in endometrial hyperplasia and endometrial carcinoma.
Choudhury M; Bansal S
Indian J Pathol Microbiol; 2007 Oct; 50(4):708-10. PubMed ID: 18306533
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D1 is significantly associated with stage of tumor and predicts poor survival in endometrial carcinoma patients.
Khabaz MN; Abdelrahman AS; Butt NS; Al-Maghrabi B; Al-Maghrabi J
Ann Diagn Pathol; 2017 Oct; 30():47-51. PubMed ID: 28965628
[TBL] [Abstract][Full Text] [Related]
7. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
8. Expression of the cell-cycle regulatory proteins (cyclins D1 and E) in endometrial carcinomas: correlations with hormone receptor status, proliferating indices, tumor suppressor gene products (p53, pRb), and clinicopathological parameters.
Mitselou A; Ioachim E; Zagorianakou N; Kitsiou E; Vougiouklakis T; Agnantis NJ
Eur J Gynaecol Oncol; 2004; 25(6):719-24. PubMed ID: 15597850
[TBL] [Abstract][Full Text] [Related]
9. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
10. Immunoexpression of Cyclin D1 and PTEN in Various Endometrial Pathologies.
Shawana S; Kehar SI; Masood S; Aamir I
J Coll Physicians Surg Pak; 2016 Apr; 26(4):277-82. PubMed ID: 27097697
[TBL] [Abstract][Full Text] [Related]
11. Progressive derailment of cell cycle regulators in endometrial carcinogenesis.
Horrée N; van Diest PJ; van der Groep P; Sie-Go DM; Heintz AP
J Clin Pathol; 2008 Jan; 61(1):36-42. PubMed ID: 17483252
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma is correlated with histological grade and proliferative activity, but not with prognosis.
Nishimura Y; Watanabe J; Jobo T; Kato N; Fujisawa T; Kamata Y; Kuramoto H
Anticancer Res; 2004; 24(4):2185-91. PubMed ID: 15330159
[TBL] [Abstract][Full Text] [Related]
13. The extent of cyclin D1 expression in endometrial pathologies and relevance of cyclin D1 with the clinicopathological features of endometrioid endometrial carcinoma.
Yildirim HT; Nergiz D; Sadullahoglu C; Akgunduz Z; Yildirim S; Dogan S; Sezer C
Indian J Pathol Microbiol; 2020; 63(3):412-417. PubMed ID: 32769330
[TBL] [Abstract][Full Text] [Related]
14. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.
Kimura F; Watanabe J; Hata H; Fujisawa T; Kamata Y; Nishimura Y; Jobo T; Kuramoto H
J Cancer Res Clin Oncol; 2004 Mar; 130(3):161-8. PubMed ID: 14689303
[TBL] [Abstract][Full Text] [Related]
15. CyclinD1, a prominent prognostic marker for endometrial diseases.
Liang S; Mu K; Wang Y; Zhou Z; Zhang J; Sheng Y; Zhang T
Diagn Pathol; 2013 Aug; 8():138. PubMed ID: 23947899
[TBL] [Abstract][Full Text] [Related]
16. Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables.
Kyushima N; Watanabe J; Hata H; Jobo T; Kameya T; Kuramoto H
J Cancer Res Clin Oncol; 2002 Jun; 128(6):307-12. PubMed ID: 12073048
[TBL] [Abstract][Full Text] [Related]
17. [Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions].
Xiong Y; Xiong YY; Zhou YF
Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):594-9. PubMed ID: 20079187
[TBL] [Abstract][Full Text] [Related]
18. Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas.
Nikaido T; Li SF; Shiozawa T; Fujii S
Cancer; 1996 Sep; 78(6):1248-53. PubMed ID: 8826947
[TBL] [Abstract][Full Text] [Related]
19. Papillary proliferation of the endometrium: a clinicopathologic study of 59 cases of simple and complex papillae without cytologic atypia.
Ip PP; Irving JA; McCluggage WG; Clement PB; Young RH
Am J Surg Pathol; 2013 Feb; 37(2):167-77. PubMed ID: 23211295
[TBL] [Abstract][Full Text] [Related]
20. Expression of the retinoblastoma-related gene Rb2/p130 is downregulated in atypical endometrial hyperplasia and adenocarcinoma.
Susini T; Massi D; Paglierani M; Masciullo V; Scambia G; Giordano A; Amunni G; Massi G; Taddei GL
Hum Pathol; 2001 Apr; 32(4):360-7. PubMed ID: 11331952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
